Loading
2 insiders bought €74k of shares over the last 90 days, the latest filed 29 Sept 2026.
SenesTech, Inc.: what insiders have been doing
SenesTech, Inc. is a Energy company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 4 insiders published 22 filings.
Both sides are active: 20 purchases worth €434k and 2 sales worth €147, from 2 insiders and 2 insiders respectively. The totals do not cover 5 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €248k, bought by Glenbrook Capital Management and made public on 17 March 2026. The buyers include 1 major shareholder and 1 chief executive.
Compared with its exchange (5,810 companies, median 19 filings), a count of 22 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 21 purchases and 2 sales.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 29 September 2026, which is 19 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at RGC Resources Inc and Terawulf Inc. also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
25
Thresholds
n/a
Buy Volume
€499,419
21 ops. · all time
Sell Volume
€147
2 ops. · all time
Who traded when
BuySaleGlenbrook Capital Management13 buys
Michael Edell7 buys
Jacob Steven Leach1 sale
Matthew K. Szot1 sale
Since the insiders bought
- -25.7%Entry US$0.86 · Close 14 Oct 2026 US$0.64
- -49.2%Entry US$1.26 · Close 14 Oct 2026 US$0.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,001 of 24,148 companies
21.0
score / 100
Value0
Quality42
FCF yld-168%
Earn yld-182%
EV/EBITDA·
ROE-107%
Gross mgn62%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.64
Analyst consensus
2 analysts1.00/5
US$3.50Target US$6.75(+955%)US$10.00
Income statement
RevenueUS$2.2M
Gross profitUS$1.4M62% margin
EBITDA-US$6.2M-280% margin
Net income-US$6.4M-294.7% margin
Valuation
P/Book0.6x
Beta0.26
Balance sheet & cash
Market capUS$3.5M
Total debtUS$2.7M
Free Cash Flow-US$5.9M
Debt / Equity43%
Profitability & ownership
ROE-107.4%
ROA-45.5%
% insiders4.3%
% institutions29.3%
Last declaration on 29 September 2026
Declarations25 total
2,000 shares@ US$0.64440.033% mcap20.0% of flowCommon StockSEC:0001628280-26-063849:0
Canonical exit: 27 Dec 2026 (T+90)
1,000 shares@ US$0.840.020% mcap16.0% of flowCommon StockSEC:0001628280-26-062063:0
Canonical exit: 13 Dec 2026 (T+90)
1,000 shares@ US$0.850.020% mcap16.2% of flowCommon StockSEC:0001628280-26-061448:1
Canonical exit: 8 Dec 2026 (T+90)
1,000 shares@ US$0.890.021% mcap16.9% of flowCommon StockSEC:0001628280-26-061448:0
Canonical exit: 8 Dec 2026 (T+90)
1,000 shares@ US$1.210.028% mcap23.2% of flowCommon StockSEC:0001628280-26-057423:0
Canonical exit: 12 Nov 2026 (T+90)
15,000 shares@ US$1.29620.45% mcap3.9% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-003373:0
Canonical exit: 4 Nov 2026 (T+90)
6,490 shares@ US$1.29770.20% mcap1.7% of flowCommon StockSEC:0000902664-26-003373:1
Canonical exit: 5 Nov 2026 (T+90)
35,000 shares@ US$1.47341.21% mcap10.5% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-003205:0
Canonical exit: 18 Oct 2026 (T+90)
1,000 shares@ US$1.42990.034% mcap27.6% of flowCommon StockSEC:0001628280-26-047673:0
Canonical exit: 5 Oct 2026 (T+90)
3,990 sharesCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-002947:0
Canonical exit: 22 Sept 2026 (T+90)
9,442 sharesCommon StockSEC:0000902664-26-002947:1
Canonical exit: 23 Sept 2026 (T+90)
6,812 sharesCommon StockSEC:0000902664-26-002947:2
Canonical exit: 24 Sept 2026 (T+90)
5,172 sharesCommon StockSEC:0000902664-26-002947:3
Canonical exit: 27 Sept 2026 (T+90)
1,000 sharesCommon StockSEC:0001628280-26-041901:0
Canonical exit: 6 Sept 2026 (T+90)
3,000 shares@ US$1.4690.054% mcap0.9% of flowCommon Stock, $0.001 par value per shareSEC:0000902664-26-002222:0
Canonical exit: 27 Jul 2026 (T+90)
146,249 shares@ US$1.951757.8% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-001650:0
Canonical exit: 11 Jun 2026 (T+90)
40,807 shares@ US$2.291118.4% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-001203:0
Canonical exit: 18 May 2026 (T+90)
8,000 shares@ US$1.73422.7% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-001004:0
Canonical exit: 12 May 2026 (T+90)
5,685 shares@ US$1.82472.0% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-000780:0
Canonical exit: 5 May 2026 (T+90)
5,399 shares@ US$1.87182.0% of flowCommon Stock, $0.001 par value per share ("Common Stock")SEC:0000902664-26-000679:0
Canonical exit: 30 Apr 2026 (T+90)
62 shares@ US$2.710.2% of flowCommon StockSEC:0001628280-25-053306:0
1 shares@ US$2.75100.0% of flowCommon StockSEC:0001628280-25-052557:0
18,799 shares0Common StockSEC:0001628280-23-020358:0
18,797 shares0Common StockSEC:0001209191-22-061723:0
50,000 shares@ US$1.537799.8% of flowCommon StockSEC:0001225208-21-011565:0
Canonical exit: 14 Nov 2021 (T+90)
25 of 25 declarations
About SenesTech, Inc.
SenesTech, Inc. (ticker: SNES) is a U.S.-listed company trading on the Nasdaq Stock Market in the United States. It is a small-cap, niche environmental and specialty pest-management business rather than a broad-based industrial supplier. The company was incorporated in the State of Nevada in July 2004 and is headquartered in Phoenix, Arizona, where it also operates its manufacturing site. For French, Belgian, and Swiss investors, SenesTech is best understood as a differentiated commercial-stage company focused on a specific and relatively underserved segment: fertility control for rat populations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680378/000162828025012408/snes-20241231.htm?utm_source=openai))
SenesTech’s core business is built around proprietary solutions designed to manage animal pest populations through fertility control instead of traditional lethal control. Its flagship product is ContraPest, which the company describes as the only EPA-registered birth control product for both male and female rats. The portfolio also includes Evolve and the Elevate Bait System, which extends the company’s reach into additional use cases, including agricultural settings. This gives SenesTech a clear product identity: it is not a general pest-control company, but a specialist in humane rodent population management with a sustainability-oriented value proposition. ([senestech.com](https://senestech.com/pages/about?utm_source=openai))
Read moreShow less
From a competitive standpoint, the company’s appeal lies in its differentiation. Traditional rodent control relies heavily on poisons and traps, whereas SenesTech positions its technology as a longer-term population-reduction tool that can be used by pest management professionals, zoos, sanctuaries, and agricultural customers. That specialization may create strategic advantages in accounts where public perception, safety, or sustainability matter, but it also means the company depends on customer education, regulatory approvals, and professional adoption to scale. In other words, SenesTech competes more on product uniqueness than on price or distribution breadth. ([senestech.com](https://senestech.com/pages/humane-rat-control?utm_source=openai))
Geographically, SenesTech’s operations are centered in the United States. The company has also emphasized national availability for some products, including the Elevate Bait System, after California regulatory approval expanded its market reach. That suggests a U.S.-centric commercialization model with potential for broader penetration across fifty states, though the business remains early in its scaling phase. ([senestech.com](https://senestech.com/blogs/news/elevate-bait-system%E2%84%A2-with-contrapest%C2%AE-is-now-available-in-california?utm_source=openai))
Recent corporate developments highlight a transitional period in leadership. In January 2026, CEO Joel L. Fruendt announced his retirement, with his departure tied to the earlier of June 30, 2026 or the appointment of a successor. On May 6, 2026, the company appointed Michael Edell as President and Chief Executive Officer. The company also continued to file SEC reports around year-end 2025 and the first quarter of 2026, underscoring ongoing public-market disclosure as it executes through this leadership change. Overall, SenesTech is a Nasdaq-listed U.S. micro-cap with an innovation-led thesis centered on humane rodent fertility control, regulatory expansion, and commercial adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680378/000162828026003905/snes-20260128.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
